Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
HRK Palmitoylethanolamide Raw Materials Powder on sale
Product Overview:
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that belongs to the class of nuclear factor agonists. It has been shown to bind to nuclear receptors (NRs) and exert a large variety of biological functions related to chronic pain and inflammation.
HRK Palmitoylethanolamide Raw Materials Powder on sale Attributes
CAS:544-31-0
MF:C18H37NO2
MW:299.49
EINECS:208-867-9
Specification: 99% min Palmitoylethanolamide Powder
Sample:Palmitoylethanolamide Powder
Packaging:1kg/bag, 25kg/drum
Brand: Raw Materials
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
HRK Palmitoylethanolamide Raw Materials Powder on sale Details
Palmitoylethanolamide is an organic synthesis intermediate and a pharmaceutical intermediate, which can be used in laboratory research and development processes and chemical and pharmaceutical research and development processes.
PEA has been shown to have anti-inflammatory, antinociceptive, neuroprotective, and anticonvulsant properties. PEA has been explored in humans for various pain states in different clinical trials, for inflammatory and pain syndromes.
Uses of Palmitoylethanolamide.
Has anti-inflammatory, antinociceptive, neuroprotective, and anticonvulsant properties.
In vitro studies of Palmitoylethanolamide.
PEA effectively protects rat cerebellar granule cells from glutamate toxicity and enhances microglial motility. In mitochondrial fragments of cells stimulated with PEA, the expression of steroidogenic rapid regulatory protein (StAR) and P450scc, which include some neurosteroid-forming proteins, is increased.
PEA also has protective effects: such as reducing malondialdehyde formation in cells treated with L-buthionine-(S,R)-sulfoximine, which causes glutathione deficiency. The effect of PEA can be partially inhibited by finasteride (5a-reductase inhibitor).
Product method of Bulk Palmitoylethanolamide Powder.
